NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
22 December 2024
| Name: | PHARMAUST LIMITED (PAA) (This company subsequently changed its name to NEURIZON THERAPEUTICS LIMITED. You should refer to that name for Status.) | ||||||
| ISIN: | AU000000PAA1 | ||||||
| Date of Listing: | 05 October 2001 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to NEURIZON THERAPEUTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
ACN: 094 006 023ABN: 35 094 006 023
Registration Date: 03 August 2000
Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now NEURIZON THERAPEUTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| NEURIZON THERAPEUTICS LIMITED | 15/10/2024 | |
| PHARMAUST LIMITED | 26/11/2004 | 15/10/2024 |
| ECHO TECHNOLOGIES LIMITED | 26/11/2004 |
Computershare Perth
Level 17, 221 St Georges Terrace, Perth WA 6000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to Neurizon Therapeutics Limited | 15/10/2024 |
The suspension of trading in the securities of PharmAust will be lifted from the commencement of trading on Thursday, 18 June 2020, following the release by PAA of an announcement regarding results from SARS-CoV-2 repeat preliminary experiments. | 18/06/2020 |
Monepantel and monepantel sulfone treatment both reduce SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation. Repeat preliminary experiment data demonstrate suppression of virus infectivity by approximately 95% in cell culture by each drug. Preparations are being made for Phase 1 trial. | 18/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of results from the SARS-CoV-2 repeat experiments. | 15/06/2020 |
The suspension of trading in the securities of PharmAust Limited will be lifted immediately following the release by PAA of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 04/06/2020 |
Monepantel treatment reduces SARS-CoV-2 virus replication in tissue culture (based upon preliminary experiments). Monepantel treatment reduces SARS-CoV-2 cell-to-cell infectivity in tissue culture (based upon preliminary experiments). Promising early data demonstrating suppression of virus by 50-95% requires further confirmation in repeat and more comprehensive studies. | 04/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 02/06/2020 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 12/11/2015 |
we understand that on or about this date the company made an in specie distribution of 1 share in Diashi Mining Limited for every 29.24 shares in the company | 22/11/2012 |
shares reinstated to quotation | 18/10/2007 |
lodges 2007 Annual Report and confirms its Announcement of 28 September 2007 that it had been unable to lodge its Full Final Accounts due to the failure of its 40% owned subsidiary, Commonwealth Biotechnologies Inc ("BI"), to provide audited figures in confirmation of its final management accounts | 12/10/2007 |
the application for an interlocutory injunction brought by Chimaera Capital Limited ("himaera") against the Company's current Entitlement Issue was dismissed in the Federal Court yesterday - despite the company requesting information from Commonwealth Biotechnologies Inc ("BI") (of which Dr D'Sylva remains Managing Director) since mid-July 2007 - it has still not received it - this is the only reason for the Company's suspension | 05/10/2007 |
shares suspended from quotation as the company failed to lodge its financial statements | 02/10/2007 |
shares reinstated to quotation | 14/02/2007 |
ADVANCE HEALTHCARE GROUP LIMITED has deferred an equity placement to raise $400,000 until Pharmaust's position in relation to its proposed takeover announced on 5 January 2007 has been clarified | 13/02/2007 |
shares suspended from quotation pending release of an announcement | 09/02/2007 |
name changed from Echo Technologies Limited | 26/11/2004 |
name changed to Neurizon Therapeutics Limited | 15/10/2024 |
The suspension of trading in the securities of PharmAust will be lifted from the commencement of trading on Thursday, 18 June 2020, following the release by PAA of an announcement regarding results from SARS-CoV-2 repeat preliminary experiments. | 18/06/2020 |
Monepantel and monepantel sulfone treatment both reduce SARS-CoV-2 (COVID-19) cell-to-cell infectivity in cell culture in a repeat preliminary experimental evaluation. Repeat preliminary experiment data demonstrate suppression of virus infectivity by approximately 95% in cell culture by each drug. Preparations are being made for Phase 1 trial. | 18/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of results from the SARS-CoV-2 repeat experiments. | 15/06/2020 |
The suspension of trading in the securities of PharmAust Limited will be lifted immediately following the release by PAA of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 04/06/2020 |
Monepantel treatment reduces SARS-CoV-2 virus replication in tissue culture (based upon preliminary experiments). Monepantel treatment reduces SARS-CoV-2 cell-to-cell infectivity in tissue culture (based upon preliminary experiments). Promising early data demonstrating suppression of virus by 50-95% requires further confirmation in repeat and more comprehensive studies. | 04/06/2020 |
The securities of PharmAust Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of PAA, pending the release of an announcement regarding disclosure of preliminary results from a pre-clinical trial. | 02/06/2020 |
we understand that on or about this date the company consolidated its shares 1 for 20 | 12/11/2015 |
we understand that on or about this date the company made an in specie distribution of 1 share in Diashi Mining Limited for every 29.24 shares in the company | 22/11/2012 |
shares reinstated to quotation | 18/10/2007 |
lodges 2007 Annual Report and confirms its Announcement of 28 September 2007 that it had been unable to lodge its Full Final Accounts due to the failure of its 40% owned subsidiary, Commonwealth Biotechnologies Inc ("BI"), to provide audited figures in confirmation of its final management accounts | 12/10/2007 |
the application for an interlocutory injunction brought by Chimaera Capital Limited ("himaera") against the Company's current Entitlement Issue was dismissed in the Federal Court yesterday - despite the company requesting information from Commonwealth Biotechnologies Inc ("BI") (of which Dr D'Sylva remains Managing Director) since mid-July 2007 - it has still not received it - this is the only reason for the Company's suspension | 05/10/2007 |
shares suspended from quotation as the company failed to lodge its financial statements | 02/10/2007 |
shares reinstated to quotation | 14/02/2007 |
ADVANCE HEALTHCARE GROUP LIMITED has deferred an equity placement to raise $400,000 until Pharmaust's position in relation to its proposed takeover announced on 5 January 2007 has been clarified | 13/02/2007 |
shares suspended from quotation pending release of an announcement | 09/02/2007 |
name changed from Echo Technologies Limited | 26/11/2004 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 10/05/2023 | Sam Wright | 50,000 | $0.082 | $4,100 |
| 10/03/2023 | Sam Wright | 85,000 | $0.087 | $7,356 |
| 09/01/2023 | Sam Wright | 165,000 | $0.070 | $11,571 |
| 13/09/2022 | Sam Wright | 250,000 | $0.075 | $18,750 |
| 24/08/2021 | Sam Wright | 500,000 | $0.085 | $42,500 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Sergio Duchini | Non Exec Chairman | 17/05/2024 |
| John Clark | Managing Director, Interim CEO | 09/05/2024 |
| Kathryn MacFarlane | Non Exec Director | 17/06/2024 |
| Marcus Hughes | Non Exec Director | 09/05/2024 |
| Stefan Ross | Company Secretary | 24/05/2024 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Michael Thurn | Managing Director, CEO | 01/09/2023 | 23/08/2024 |
| Sam Wright | Interim Chairman, Company Secretary | 01/10/2008 | 17/05/2024 |
| Neville Bassett | Non Exec Director | 02/10/2018 | 14/05/2024 |
| Roger Aston | Non Exec Chairman | 12/08/2013 | 09/05/2024 |
| Thomas Duthy | Non Exec Director | 05/02/2024 | 09/05/2024 |
| Robert Bishop | Non Exec Director | 29/10/2013 | 09/05/2024 |
| Wayne Best | Independent Director | 12/11/2004 | 04/10/2018 |
| Richard Hopkins | CEO | 07/03/2017 | 25/05/2018 |
| David Morris | Non Exec Director | 12/08/2013 | 29/10/2015 |
| Henry Gulev | Non Exec Director | 23/08/2007 | 29/10/2013 |
| Bryant McLarty | Executive Chairman | 25/07/2003 | 12/08/2013 |
| Gregory Cunnold | Non Exec Director | 12/07/2011 | 07/11/2012 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
